MARKET

SAGE

SAGE

SAGE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

61.26
-0.59
-0.95%
Opening 14:50 09/23 EDT
OPEN
61.21
PREV CLOSE
61.85
HIGH
62.19
LOW
59.85
VOLUME
209.58K
TURNOVER
--
52 WEEK HIGH
166.01
52 WEEK LOW
25.01
MARKET CAP
3.18B
P/E (TTM)
-5.1911
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
SAGE Therapeutics Inc (SAGE): Hedge Funds In Wait-and-See Mode
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index
Insider Monkey · 6d ago
Sage Therapeutics (NASDAQ:SAGE) Share Prices Have Dropped 65% In The Last Year
It is a pleasure to report that the Sage Therapeutics, Inc. (NASDAQ:SAGE) is up 50% in the last quarter. But that...
Simply Wall St. · 09/15 14:56
Sage Therapeutics Upgraded on Potential for Depression Drug
Wedbush analyst Laura Chico upgraded Sage Therapeutics to outperform on the potential of a developmental drug to treat depression.
TheStreet.com · 09/11 18:38
Stocks making the biggest moves midday: Peloton, Oracle, Nikola, Domino's & more
Peloton and Oracle got a lift from better-than-expected earnings. Nikola took a massive hit as its CEO disputes fraud allegations.
CNBC.com · 09/11 16:11
Benzinga's Top Upgrades, Downgrades For September 11, 2020
Upgrades * According to Wedbush, the prior rating for Sage Therapeutics Inc (NASDAQ: SAGE) was changed from Neutral to Outperform. Sage Therapeutics earned $2.08 in the second quarter, compared to $3.28 in the year-ago quarter. The current stock performance of Sage Therapeutics shows a 52-week-high
Benzinga · 09/11 13:38
Sage Therapeutics (SAGE) in Focus: Stock Moves 5.1% Higher
Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Zacks · 09/11 12:41
Addressing mental health is critical to getting Americans back to work, Sage Therapeutics CEO says
With depression rates up amid the economic and health crises, mental health should be treated like a physical illness, Sage Therapeutics CEO Jeff Jonas said on "Mad Money."
CNBC.com · 09/11 00:08
Sage Therapeutics bucks market selloff on pipeline prospects
Sage Therapeutics ([[SAGE]] +5.2%) is up on double normal volume, although down over 6% from its intraday high of $57.98, on the heels of its pipeline update today. Highlights:Co. has developed a
Seekingalpha · 09/10 19:41
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SAGE. Analyze the recent business situations of SAGE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SAGE stock price target is 78.72 with a high estimate of 195.00 and a low estimate of 35.00.
EPS
Institutional Holdings
Institutions: 406
Institutional Holdings: 63.58M
% Owned: 122.32%
Shares Outstanding: 51.97M
TypeInstitutionsShares
Increased
81
7.11M
New
102
-1.29M
Decreased
54
7.03M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.65%
Pharmaceuticals & Medical Research
-0.86%
Key Executives
Chairman/Director
Kevin Starr
President/Chief Executive Officer/Director
Jeffrey Jonas
Chief Financial Officer/Treasurer
Kimi Iguchi
Chief Operating Officer
Michael Cloonan
Senior Vice President/General Counsel/Secretary
Anne Cook
Chief Scientific Officer
Albert Robichaud
Other
Stephen Kanes
Independent Director
Elizabeth Barrett
Independent Director
Michael Cola
Independent Director
James Frates
Independent Director
Geno Germano
Independent Director
George Golumbeski
Independent Director
Asha Nayak
Independent Director
Steven Paul
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SAGE
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of SAGE Therapeutics Inc stock information, including NASDAQ:SAGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAGE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SAGE stock methods without spending real money on the virtual paper trading platform.